Purolite opens 100,000L agarose plant in Wales

By Flora Southey contact

- Last updated on GMT

The first minister of Wales, Rt Hon Carwyn Jones, opens Purolite's new facility in Wales
The first minister of Wales, Rt Hon Carwyn Jones, opens Purolite's new facility in Wales
Purolite Life Sciences’ new agarose manufacturing plant will supply chromatography resins up to 70% cheaper than GE’s offerings, says executive.

The 100,000L plant, which opened its doors yesterday in Llantristant, UK, will manufacture a range of chromatography products, including the notoriously expensive​ bioprocessing resin, Protein A.

Protein A is a recombinant protein used to purify monoclonal antibodies (mAbs) from harvest cell culture for the manufacture of biologics. To date, Protein A has largely been made and supplied by GE Healthcare Life Sciences.

Don Brodie, Purolite's executive VP
Don Brodie, Purolite's executive VP

However, according to Purolite, the new Wales facility will enable the sale of chromatography resins up to 70% cheaper than GE.

“We know that today, the market is held by one major supplier, and our goal was clear, to be the only credible alternative to today’s Protein A resin,”​ said sales director, life sciences agarose, Chris Major, at the opening yesterday.

Purolite has created “game-changing”​ resins that “push the boundaries of productivity, and significantly reduce manufacturing costs,” ​he added.

GE did not respond to questions regarding growing competition in the market, but Sofie Stille, general manager of bioprocess downstream resins, GE Healthcare Life Sciences, said the company continues to invest in innovation to provide high productivity resins and capacity.

“We have a strong dedication to support the biopharma industry and patients around the world and for this we make significant contributions,” ​she added.

Purolite's sales director, life sciences agarose, Chris Major, at the opening yesterday
Purolite's sales director, life sciences agarose, Chris Major

Jetting technology

Purolite’s chromatography beads are made in two ways: by standard polymerisation, whereby both fine and coarse particles are produced, before you “squeeze out the fraction that you need”, ​and a sophisticated ‘jetting’ process, explained global operations director, Satish Bapat.

It is this patented jetting technology, designed to produce uniform size agarose beads, that will be a major factor in reducing costs, we were told.

“The beauty of jetting is that you can actually dial in the kind of particle size you require. All round, jetted product will be far more cost-effective,” ​said Bapat.

Bioindustry a ‘huge growth area’ in Wales

At the opening, Rt Hon Carwyn Jones told delegates the plant, which was in part funded by the Welsh government, represents a close relationship between industry and government.

“We know that [our £500,000 ($650,326)] investment will help to improve and sustain the competitiveness of the plant here in Wales,” ​said Jones.

“It fits very well with the direction we want to take Wales. We know that the bioindustrial sector is a huge growth area for us. We want Wales to develop an image in the world of expertise in this field,” ​he added.

Related news

Show more

Related products

show more

Liposomal and Nanoparticle Technology

Liposomal and Nanoparticle Technology

Pfizer CentreOne | 18-Nov-2022 | Technical / White Paper

Medical science is continuously searching for better ways to administer drugs into the body and to maximize the therapeutic effectiveness of the drugs...

Connectivity & Integration in Biomanufacturing

Connectivity & Integration in Biomanufacturing

Wheeler Bio | 17-Nov-2022 | Technical / White Paper

As the Pharma 4.0 initiative sets a new industry paradigm, more biomanufacturing companies are asking how they can design and build facilities that apply...

GMP manufacturing of buffers and liquid blends

GMP manufacturing of buffers and liquid blends

Actylis – The Partner of Choice | 16-Nov-2022 | Technical / White Paper

Actylis manufactures buffers, process solutions, cleaning solutions, Water for Injection (WFI) for further processing, and custom liquid blends in compliance...

Custom manufacturing of protease inhibitor PMSF

Custom manufacturing of protease inhibitor PMSF

Actylis – The Partner of Choice | 09-Nov-2022 | Technical / White Paper

By combining 75+ years of manufacturing and sourcing expertise, Actylis provides a wide portfolio of GMP ingredients to the pharma & biopharma market,...

Related suppliers

Follow us

Products

View more

Webinars